CD19 and lymphoma: According to a clinical study by Kochenderfer et al., out of 15 patients with advanced B-cell malignancies who received CD19 CAR-T-cell therapy, 8 of them experienced complete remission, 4 showed partial remission, 2 were not responsive, and 1 had stable lymphoma [35].